Helsinn Group Announces European Medicines Agency’s (EMA) Acceptance for review of the Marketing Authorization Application (MAA) for Infigratinib for Patients with Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 Fusions or Rearr

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence